The phase 2b REZOLVE-AD trial enrolled 393 adults with moderate-to-severe atopic dermatitis across approximately 110 global ...

Apogee Therapeutics Inc. (NASDAQ:APGE) stock is experiencing a significant surge, trading almost 29% higher in premarket on Monday. This substantial increase in stock price follows the release of ...

Atopic dermatitis imposes a significant financial burden, costing over $4 billion annually, with federal assistance programs like SNAP improving healthcare affordability. A study using NHIS data found ...

APEX Part A met all primary and key secondary endpoints and exceeded trial objectives, including 71.0% decrease from baseline in EASI at Week 16 APG777 demonstrated EASI-75 of 66.9% (42.5% ...

Monthly lebrikizumab maintenance dosing sustained clear or almost-clear skin for up to three years in the vast majority (more than 80%) of ADvocate 1 and 2 responders Nearly 87 percent of patients ...

Please provide your email address to receive an email when new articles are posted on . Dupilumab was able to improve lichenification among patients aged 6 to 88 years with atopic dermatitis. Patients ...

Please provide your email address to receive an email when new articles are posted on . Systemic control of inflammation with upadacitinib may reduce cardiovascular event risk in adults with atopic ...

Once-daily, effective, safe, and well-tolerated ZORYVE cream 0.05% now commercially available for children as young as age 2 ZORYVE cream 0.05% provides rapid clearance of atopic dermatitis ZORYVE can ...

JERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN), a global healthcare company with a mission to improve the health of women throughout their lives, today announced that the U.S. Food and Drug ...

Adolescents with AD experience higher emotional distress, while younger children face more sleep disturbances and itching-related issues. The study emphasizes the need for age-specific treatment ...

Atopic dermatitis, which is characterized by a disturbed skin barrier, robust type 2 helper T-cell (Th2)–mediated immune responses to numerous environmental antigens, susceptibility to cutaneous ...